文献速递肿瘤 PET/CT

局部晚期食管鳞癌三模态治疗中容积PET/CT的作用与预后价值

Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-08-08

该研究纳入275例接受三模态治疗的局部晚期食管鳞癌患者,评估治疗前后容积PET/CT参数与病理完全缓解(pCR)及生存的关系。pCR率为27.3%,pre-TLG、post-MTV和%SUVavg下降是pCR的显著预测因素,其中pre-TLG预测最佳(cutoff 205.67,AUC 0.591)。体力状态、病理肿瘤大小、病理N状态和post-MTV是总生存的显著预测因素。

要点

  • pre-TLG、post-MTV和%SUVavg下降可预测pCR,pre-TLG预测最佳。
  • 体力状态、病理肿瘤大小、病理N状态和post-MTV与总生存显著相关。

核心结论

  • pre-TLG、post-MTV和%SUVavg下降是局部晚期食管鳞癌三模态治疗后pCR的预测因素。
  • 体力状态、病理肿瘤大小、病理N状态和post-MTV是总生存的显著预测因素。

研究设计与样本

  • 回顾性评估275例T3-T4aN0M0和T1-T4aN1-N3M0的食管鳞癌患者,均接受三模态治疗。
  • 分析同步放化疗前后容积PET/CT参数与术后pCR、临床-影像-病理特征及生存的相关性。

主要发现

  • 275例中75例(27.3%)达到pCR,其中61例(80.9%)显示5年生存。
  • pre-TLG(OR=0.318,95%CI 0.169-0.600)、post-MTV(OR=0.572,95%CI 0.327-0.999)和%SUVavg下降(OR=2.976,95%CI 1.608-5.507)是pCR的显著预测因素。
  • pre-TLG预测pCR最佳,最佳cutoff值为205.67,AUC为0.591。
  • 体力状态(HR=5.171,95%CI 1.737-15.397)、病理肿瘤大小(HR=1.645,95%CI 1.351-2.002)、病理N状态(N1 HR=1.572,95%CI 1.010-2.446;N2 HR=3.088,95%CI 1.845-5.166)和post-MTV(HR=1.506,95%CI 1.033-2.195)是总生存的显著预测因素。

关键数值与推荐

  • pCR定义为术后病理完全缓解,275例中75例(27.3%)达到pCR。
  • pre-TLG预测pCR的最佳cutoff值为205.67,AUC为0.591。

临床怎么用

  • 治疗前pre-TLG、治疗后post-MTV及%SUVavg下降可用于辅助预测局部晚期食管鳞癌三模态治疗后的pCR。
  • 结合体力状态、病理肿瘤大小、病理N状态和post-MTV可辅助评估总生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the role of positron emission tomography/computed tomography (PET/CT) in predicting pathologic complete response (pCR) and identify relevant prognostic factors from clinico-imaging-pathologic features of locally advanced esophageal squamous cell carcinoma (eSCC) patients undergoing trimodality therapy. METHODS: We evaluated 275 patients with eSCCs of T3-T4aN0M0 and T1-T4aN1-N3M0 who received trimodality therapy. We correlated volume-based PET/CT parameters before and after concurrent chemoradiation therapy with pCR after surgery, clinico-imaging-pathologic features, and patient survival. RESULTS: pCR occurred in 75 (27.3%) of 275 patients, of whom 61 (80.9%) showed 5-year survival. Pre-total lesion glycolysis (pre-TLG, OR = 0.318, 95% CI 0.169 to 0.600), post-metabolic tumor volume (post-MTV, OR = 0.572, 95% CI 0.327 to 0.999), and % decrease of average standardized uptake value (% SUVavg decrease, OR = 2.976, 95% CI = 1.608 to 5.507) were significant predictors for pCR. Among them, best predictor for pCR was pre-TLG with best cutoff value of 205.67 and with AUC value of 0.591. Performance status (HR = 5.171, 95% CI 1.737 to 15.397), pathologic tumor size (HR = 1.645, 95% CI 1.351 to 2.002), pathologic N status (N1, HR = 1.572, 95% CI 1.010 to 2.446; N2, HR = 3.088, 95% CI 1.845 to 5.166), and post-metabolic tumor volume (HR = 1.506, 95% CI 1.033 to 2.195) were significant predictors of overall survival. CONCLUSION: Pre-TLG, post-MTV, and % SUVavg decrease are predictive of pCR. Additionally, several clinico-imaging-pathologic factors are significant survival predictors in locally advanced eSCC patients undergoing trimodality therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Choi Y, Choi JY, Hong TH, et al. Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. Eur J Nucl Med Mol Imaging. 2021. PMID: 34365522. doi:10.1007/s00259-021-05487-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。